Sam Brusco, Associate Editor06.03.21
OrthoPediatrics completed its senior leadership transition, with David Bailey succeeding Mark Throdahl as CEO. Mark Throdahl will remain with the company as Executive Chairman.
“Over the last 10 years, it has been a privilege to work with our remarkable team leading the effort to improve the lives of children suffering from musculoskeletal disorders,” Mark Throdahl told the press. “As Executive Chairman, I look forward to remaining highly engaged with OrthoPediatrics and its strategy as well as supporting Dave in his new role as CEO. Dave has been an exemplary executive since joining OrthoPediatrics in 2007, and I have every confidence that he will bring both deep experience and leadership skills to this position. Dave will be joined by Fred Hite, who was appointed Chief Operating Officer and Chief Financial Officer last year, as the team that will lead the Company to the next level of success.”
“While Mark transitions to Executive Chairman, we must emphasize that our strategy remains unchanged. We will continue to execute on our growth plans and deliver innovative and differentiated products to pediatric surgeons to improve children’s lives,” said David Bailey, CEO. “I am very optimistic about our future and look forward to working more closely with our internal teams and the investment community.”
“Over the last 10 years, it has been a privilege to work with our remarkable team leading the effort to improve the lives of children suffering from musculoskeletal disorders,” Mark Throdahl told the press. “As Executive Chairman, I look forward to remaining highly engaged with OrthoPediatrics and its strategy as well as supporting Dave in his new role as CEO. Dave has been an exemplary executive since joining OrthoPediatrics in 2007, and I have every confidence that he will bring both deep experience and leadership skills to this position. Dave will be joined by Fred Hite, who was appointed Chief Operating Officer and Chief Financial Officer last year, as the team that will lead the Company to the next level of success.”
“While Mark transitions to Executive Chairman, we must emphasize that our strategy remains unchanged. We will continue to execute on our growth plans and deliver innovative and differentiated products to pediatric surgeons to improve children’s lives,” said David Bailey, CEO. “I am very optimistic about our future and look forward to working more closely with our internal teams and the investment community.”